The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

The approval is supported by data from clinical trials, including pharmacodynamic and pharmacokinetic responses in adults and ...

Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

So as way of background, EZH2 is an epigenetic enzyme that's overexpressed in castrate-resistant prostate cancer, and it's ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...

Antibiotic therapy relies on understanding both pharmacokinetics (PK) and pharmacodynamics (PD), which respectively address drug absorption, distribution, and elimination, and the relationship between ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

AvailTM trial exceeded enrollment target; topline results expected in Q3 2025CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...